Multi-omics Insights Into Type 2 Diabetes

Abstract

Type-2 diabetes (T2D) is a chronic health burden that is characterized by insulin deficiency inducing dysfunctional glucose homeostasis maintenance or hyperglycemia. This phenomenon arises from a combination of deficient insulin secretion by pancreatic islet β-cells, tissue insulin resistance, and/or an inadequate compensatory insulin secretory response. To date, complete “curing” of T2D has not been reported, with current treatments focused on managing complications that could affect major organs and tissues including heart and blood vessels, nerve, kidneys, eyes, skin, and more. The aim of this study is to perform a multi-omics analysis that includes transcriptomics, proteomics, and metabolomics to identify potential therapeutic targets that can improve the treatment of T2D. The results from this study included several differentially expressed genes/proteins (DEGs) and enriched intracellular signaling pathways that consistently appear across different datasets and -omics data types.

Keywords

Type-2 diabetes, T2D, multiomics, multi omics analysis software, CDIAM multi omics studio, type-2 diabetes review, type-2 diabetes biomarkers and targets